To test this prediction, we analyzed RNAseq data from a phase 2 study of neoadjuvant abemaciclib in postmenopausal, HR+, HER2- breast cancer patients (neoMONARCH, NCT02441946 [41]) and identified top scoring pathways via gene set enrichment analysis (GSEA). The gene discussed is ERBB2; the disease is breast carcinoma.